| Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy (NCT03719131) | Emory University | 2019-06-05 |
| Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners (NCT03112668) | Rutgers, The State University of New Jersey | 2017-12-06 |
| Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma (NCT03229278) | Rutgers, The State University of New Jersey | 2017-10-03 |
| Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer (NCT03154190) | Stanford University | 2017-08-08 |
| Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma (NCT02748564) | Rutgers, The State University of New Jersey | 2017-03-21 |
| Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases (NCT02858869) | Emory University | 2016-10-04 |
| SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine (NCT02716948) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2016-06-23 |
| A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases (NCT02941744) | Universitair Ziekenhuis Brussel | 2016-03-01 |
| TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors (NCT02650635) | Mayo Clinic | 2016-02-05 |
| Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer (NCT02318771) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2015-02-05 |
| MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery (NCT02320305) | Mayo Clinic | 2015-01-27 |
| Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab or Pembrolizumab Therapy (NCT01789827) | Mayo Clinic | 2014-03-01 |
| Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma (NCT01970527) | University of Washington | 2014-03-01 |
| Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma (NCT01961115) | Fred Hutchinson Cancer Center | 2013-09-13 |
| Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Removed by Surgery (NCT01886235) | Roswell Park Cancer Institute | 2013-09-04 |
| Translational Study for BRAFV600 Serum and Plasma Determination in Patients With BRAFV600 Metastatic Melanoma (NCT01960634) | Grupo Español Multidisciplinar de Melanoma | 2013-04-01 |
| Study With T-cel Receptor Gene Therapy in Metastatic Melanoma (NCT02654821) | The Netherlands Cancer Institute | 2012-03-01 |
| Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors (NCT01522820) | Roswell Park Cancer Institute | 2012-03-01 |
| Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma (NCT01196416) | National Cancer Institute (NCI) | 2010-08-01 |
| Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors (NCT01131234) | National Cancer Institute (NCI) | 2010-05-01 |
| MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma (NCT00866177) | National Cancer Institute (NCI) | 2009-03-01 |
| Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma (NCT00397982) | National Cancer Institute (NCI) | 2008-01-01 |
| Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma (NCT00387751) | National Cancer Institute (NCI) | 2006-08-01 |
| Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery (NCT00110019) | National Cancer Institute (NCI) | 2005-06-01 |
| Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery (NCT01989559) | National Cancer Institute (NCI) | 2002-10-01 |
| Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma (NCT00019682) | National Cancer Institute (NCI) | 1999-12-01 |